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Social reward and social pain: overlapping neurobiological substrates
Depending on internal state and environment, interactions with conspecifics in humans and animals may be experienced as aversive or pleasurable. Indeed, individuals may either compete for resources, territory, mates, social status or parental care (Roughgarden, 2012 ) when these are scarce or instead cooperate, play, mate, care for offspring, to ensure their survival and genetic legacy. In the latter case, social interactions can elicit pleasure and euphoria (Fehr and Camerer, 2007; Neuhaus et al., 2010; Trezza et al., 2010) and accordingly activate brain regions belonging to the reward processing circuitry. Social interaction or craving for social connection activates the nucleus accumbens (NAc) and medial prefrontal cortex (PFC) in humans (Fareri et al., 2015; Kawamichi et al., 2016; Inagaki et al., 2016a) . Conversely, activating reward regions such as ventral tegmental area (VTA) or dopaminergic raphe neurons in rodents promotes social interaction (Gunaydin et al., 2014; Matthews et al., 2016) . Pleasure associated with social experience facilitates further social contact and may lead ultimately to the structuration of a social organization (Cacioppo et al., 2011) .
As a corollary of social organization, however, rejection by peers or loss of a close relative can be felt in social species as extremely painful, as much as an amputation (Parkes, 1975) , and prolonged isolation elicits deleterious psychological and physical damages (Eisenberger et al., 2016; Filipovic et al., 2016) . Remarkably, social rejection activates similar brain regions, such as the anterior cingulate cortex (ACC), anterior insula, periaqueductal gray (PAG) and amygdala, as physical pain (Kross et al., 2011; Eisenberger, 2012; Hsu et al., 2013; Papini et al., 2015) , suggesting that indeed rejected individuals experience 'social pain', which can be relived even more easily and more intensely than physical pain (Chen et al., 2008) . Importantly, social context, whether positive (such as images of loved ones in humans) or negative (rejection), can influence physical pain perception (Defeudis et al., 1976; Puglisi-Allegra and Oliverio, 1983; Coudereau et al., 1997; Younger et al., 2010) . Together, these data suggest that affiliative and social behaviours have hijacked primary reward and pain systems to promote social interactions and avoid adverse social contexts (Nelson and Panksepp, 1998) .
At the neuronal level, many different neurotransmitters modulate social behaviour, either facilitating or inhibiting social interactions. Remarkably, most of the former are wellknown key players of the reward system, such as dopamine, noradrenaline, cannabinoids, oxytocin or opioids (Dolen et al., 2013; Coria-Avila et al., 2014; Baribeau and Anagnostou, 2015; Loureiro et al., 2016; Vanderschuren et al., 2016) , and have been initially identified as neurochemical mediators of the motivational/rewarding properties of drugs of abuse and/or as pain killers. In contrast, neurobiological substrates of social avoidance [social avoidance systems (SAS)] have been characterized as main factors of the pain, aggression or stress systems and include 5-HT, glucocorticoids and neuropeptides such as corticotropin-releasing factor, arginine vasopressin, substance P or cholecystokinin (Katsouni et al., 2009; Takahashi et al., 2012; Barik et al., 2013; Katsouni et al., 2013; Gobbroge et al., 2017) . Pro-social and anti-social neuromodulators thus compete to drive adaptive social behaviour in individuals. In the following section, we will focus on the role of opioids and, more specifically, of the opioid μ receptor, in this subtle balance.
The μ receptor is a critical neurobiological substrate of social behaviour
The opioid receptors belong to the large family of GPCRs and include three members: μ, δ and κ opioid receptors, whose preferential endogenous ligands are the opioid peptides, enkephalins, endorphins and dynorphins, respectively. The opioid system is a well-known key modulator of pain, and exogenous ligands of opioid receptors, the opiates, have been used for thousands of years as pain killers. Medicinal use of opiates, however, has also led to the discovery of their addictive properties, shedding light on a second major physiological role of opioids: modulating reward processes. The identification of opioid peptides, their receptors and respective genes has since allowed a better understanding of their mechanism of action, regarding the control of pain and reward (Le Merrer et al., 2009) as well as many other roles in stress response, respiration, food intake, gastrointestinal transit, endocrine and immune processes (Yamanaka and Sadikot, 2013; Sobczak et al., 2014; Plein and Rittner, 2017) .
In 1978, Panksepp and colleagues formulated their 'Brain Opioid Theory of Social Attachment' (BOTSA), in which social and affiliative behaviours are proposed to tightly depend on the level of endogenous opioid peptides, based notably on striking similarities between social attachment and drug addiction (Panksepp et al., 1978) . BOTSA hypothesizes that social deprivation induces social distress and contact seeking due to insufficient opioid tone (opioid withdrawal). Social contact would relieve this negative affect by triggering opioid (endorphin) release. Since then, experimental evidence has accumulated showing that μ receptors are primarily involved in pro-social effects of opioids, which are not only exclusively observed under social distress conditions (social deprivation or defeat) but also in more neutral or even positive social situations (social comfort). We review these data in the next subsections.
Role of μ receptors under social distress conditions
With regard to the role of μ receptors under social distress conditions (summary and references in Table 1 and Figure 1 ), the first evidence came from the observation that μ receptor agonists in infant rodents or monkeys can reduce the severe distress and ultrasound vocalizations (USV) triggered by separation from the mother. Similarly, in young adults, μ receptor agonists restore social interaction deficits and decrease defensive/submissive behaviour and USVs in isolated and defeated animals. Although social play is a highly rewarding and conserved behaviour in young social Najam and Panksepp, 1989 (Continues) mammals (Vanderschuren et al., 2016) , the common use is to isolate animals prior to its study, to increase social seeking (Table 1 ). In such mild negative social conditions, μ receptor agonists, delivered systemically, increase social play and motivation to play and reverse social dominance in juvenile rodents or monkeys. Furthermore, direct injection of μ receptor agonists in the NAc is sufficient to enhance social play, in accordance with the hedonic properties of μ receptor activation in this region. Besides, exposure to negative social contexts modifies brain μ receptor expression (Figure 1 ), notably in the NAc and VTA (Vanderschuren et al., 1995c; Nikulina et al., 2005; Chaijale et al., 2013; Rodriguez-Arias et al., 2016) . In contrast with agonists, opioid antagonists exacerbate social distress and USV and increase the incidence of defensive postures. Together, therefore, pharmacological data in animals suggest that μ receptor activation can relieve distress in animals experiencing aversive social situations, whereas μ receptor blockade exacerbates such distress. In humans, imaging studies have revealed the activation of μ receptors under conditions of social rejection (notably in the NAc, amygdala and PAG) that correlated with lower levels of sadness and feeling of rejection, suggesting that μ receptors in these regions play a protective or adaptive role in social pain (Hsu et al., 2013; Hsu et al., 2015) ( Figure 1 ). Whereas six other rare polymorphisms exist, the A118G polymorphism of the OPRM1 gene (coding for the μ opioid receptor), removing a potential extracellular N-glycosylation site, is commonly found in European and Asian populations (15-60%) and considered as a gain-of-function in vitro and in vivo (Kroslak et al., 2007; Sia et al., 2008) . A118G polymorphism carriers exhibit increased sensitivity to dramatic social rejection, leading to higher depression scores in adults (Way et al., 2009; Hsu et al., 2013; Slavich et al., 2014; Carver et al., 2016) , more negative personality and impaired emotional, behavioural and social skills in children (Bertoletti et al., 2012; Carver et al., 2016) . These last data suggest that μ receptor hyperactivity can be detrimental to coping with highly negative social experiences.
Role of μ receptors under neutral/positive social conditions
The role of μ receptor activation has also been extensively studied under conditions of social comfort (Table 1) . In such context, low to moderate μ receptor activation facilitates social behaviour. In rats, μ receptor agonists increase socio-sexual and sexual behaviours, bias spatial exploration in an unfamiliar environment towards social play and enhance long-term social memory. In contrast, blockade of μ receptor activity inhibits various social behaviours when administered under neutral social context in animals, including social interaction, social play, affiliative and sexual or socio-sexual behaviours. The μ receptors in the NAc play a critical role in socio-sexual behaviour, as their expression in this structure is enriched in monogamous species (Inoue et al., 2013; Ragen et al., 2015a) and intra-NAc administration of antagonists abolishes partner preference formation (Table 1 and Figure 1 ). Remarkably, administering an opioid antagonist during the first four post-natal days in mice leads to social impairment and anhedonia in adult age. In humans, psychopharmacological studies have revealed that a low dose of μ receptor agonist increases female face attractiveness and avoidance of the least attractive female faces in men. Partial agonists improve memory for happy faces, increase pleasantness ratings of neutral or social images and decrease perception of social rejection (Table 1) . Moreover, positive social stimuli such as social acceptance or pleasant social touch modify μ receptor availability in common structures (Hsu et al., 2013; Nummenmaa et al., 2016) (Figure 1 ). In contrast with agonists, opioid antagonists decrease facial emotional responses to happy faces, decrease female face attractiveness and reduce feelings of social connection in young adults. In humans, adult carriers of the A118G OPRM1 polymorphism show less avoidance of affectionate relationships and increased capacity to experience social reward (Troisi et al., 2011) , whereas child carriers display improved relationships, better resilience to aversive parental care and enhanced responses to facial expression of social and emotional stimuli (Copeland et al., 2011; Troisi et al., 2011; Bertoletti et al., 2012) . Consistent with this, A118G OPRM1 knock-in mice exhibit increased social interaction, dominance and protection from social defeat (Mague et al., 2009; Briand et al., 2015) . Similarly, the C77G polymorphism in macaques, equivalent to the human A118G polymorphism, results in higher affiliative behaviour in mothers and infants (Barr et al., 2008; Higham et al., 2011) . All these data thus converge to draw a pro-social picture for μ receptors under neutral/positive social conditions.
The particular case of excessive and/or prolonged opioid stimulation Surprisingly, however, several studies have reported that μ receptor agonists administered either acutely at a moderate to high dose or chronically at a low dose inhibit various social behaviours such as socio-sexual behaviours, maternal behaviour and duration of direct social exploration independently from the social context (Table 1) . Interestingly, in the clinics, former opiate addicts under opioid maintenance (chronic low dose) display social interaction/cognition deficits, report feeling of being unrelated and behave in an autistic way (McDonald et al., 2013; Johnson et al., 2014) . In other studies, high doses of a μ receptor agonist, given acutely or chronically, reduce socio-sexual behaviour, social play and impair long-term social memory in animals. Furthermore, exposure to high doses of opiates affects social behaviour in the long term, as mice exposed to escalating doses of morphine or heroin display severe social interaction deficit up to 7 weeks after cessation of treatment (Table 1) . Of note, brain transcription of opioid peptides is reduced after 4 weeks in abstinent animals (Becker et al., in press ) suggesting that excessive opioid stimulation results in long lasting adaptive peptide down-regulation. Accordingly, opiate-abstinent patients without substitutive therapy show low levels of circulating β-endorphin (Shi et al., 2009 ) and display reduced prefrontal response to social stimuli, pointing to social behaviour deficits (Huhn et al., 2016) . Together, these data indicate that, when excessive and/or prolonged, μ
Figure 1
Effects of regional pharmacological manipulation of μ receptors (MOR) on social behaviour and regional μ receptor expression in rodents (left panel) and humans (right panel) under social comfort (green) or social distress (black) conditions. Lateralization of brain responses (right or left hemisphere) was not taken into account for simplification purpose. Pharmacological manipulations of μ receptors and modifications in μ receptor expression (in rodents) or availability (humans) affect similar brain regions, independently from the social context. These structures mostly belong to the reward circuitry (highlighted in orange). ACC, anterior cingulate cortex; AMG, amygdala; AOB, accessory olfactory bulb; BNST, bed nucleus of stria terminalis; CC, cingulate cortex; IC, insular cortex; GP, globus pallidus; LC, locus coeruleus; LS, lateral septum; MCC, middle cingulate cortex; OFC, orbitofrontal cortex; PCC, posterior cingulate cortex; POA, preoptic area of hypothalamus; PVN, paraventricular nucleus of hypothalamus; Th, thalamus.
receptor activation can exert a deleterious influence on social behaviour.
The μ receptor balance model
In an attempt to solve the paradox of divergent effects of μ receptor stimulation on social behaviours depending on species (rodents vs. primates/humans), a 'State-dependent μ-Opioid Modulation of Social Motivation' (SOMSOM) model was recently proposed. This model postulates that the effects of μ receptor agonists and antagonists depend on the social motivational state of the animals when assessing their behaviour, namely, whether they are trying to reduce distress or seeking a pleasurable experience . In this model, the initial social context is the crucial determinant of future effects of opioid manipulation on sociability. However, although this model successfully predicts the consequences of μ receptor stimulation and inhibition under social distress or comfort conditions, it fails to account for negative consequences of intense and/or longlasting μ receptor stimulation. Extending the SOMSOM model, we propose a μ receptor balance model (Figure 2) , in which the key determinant to predict the consequences of opioid/μ receptor manipulation on social behaviour is the initial μ receptor activity. In this model, both excessive and deficient μ receptor activity negatively influence social behaviour through a classical inverted-U relationship (Johnson et al., 2014) . In a narrow window of optimal functioning, μ receptor activity could be balanced with SAS to allow adaptive social behaviour. In contrast, blunted μ receptor activity, due to social distress or pharmacological antagonism, leads to reduced social reward/motivation and leaves the field clear for SAS to elicit social withdrawal. Similarly, excessive μ receptor stimulation due to intense/prolonged exposure to opioids saturates the reward system and produces social indifference. In this framework, blocking μ receptor activity in the case of excessive tone, or stimulating μ receptor when the tone is too low, can restore normal, adaptive, social behaviour. The μ receptor balance model thus reconciles experimental discrepancies regarding the social consequences of μ receptor stimulation depending on species and social context. Manipulation of μ receptors in different social contexts might face some technical issues of other non-specific functions of the μ receptor (locomotion and sedation) affecting social behaviour. However, our conclusions are drawn on studies involving different doses of μ receptor ligands and studying different kind of social behaviours and also non-social behaviours, excluding issues regarding
Figure 2
The μ receptor balance model. Activity of μ receptors (μOR) competes with SAS to drive social behaviours. In a narrow window of optimal functioning, μ receptor activity is balanced with SAS to allow adaptive social behaviour. These conditions are ideal to detect social reward (good signal to noise ratio). On the left part of the curve, low μ receptor activity, due to social distress, pharmacological antagonism or genetic anomaly, leads to reduced social reward and/or motivation and leaves the field clear for SAS to elicit social withdrawal (insufficient signal). On the right part of the curve, excessive μ receptor activity, due to intense and/or prolonged exposure to opioid ligands or increased μ receptor expression, saturates the reward system and produces social indifference (excessive noise). Importantly, in this model, blocking μ receptor activity in the case of excessive tone, or stimulating μ receptor when the tone is too low, can restore normal, adaptive, social behaviour.
other μ receptor functions and their effects on social behaviours.
Genetic manipulations of the μ opioid receptor and autistic-like syndrome in mice
Genetic knockout of μ receptors (Oprm1 À/À ) produces severe alterations of social behaviour in mice. Indeed, mouse pups lacking μ receptors vocalize less when separated from their mother (Moles et al., 2004; Cinque et al., 2012) , juvenile Oprm1 À/À mice exhibit reduced interest in social partners (Cinque et al., 2012) , young adult Oprm1 À/À males respond less to female vocalizations (Wohr et al., 2011; Gigliucci et al., 2014) and Oprm1 À/À male and female animals display reduced social interaction and preference (Becker et al., 2014) . However, when exposed to chronic social defeat, μ receptor knockout animals show less aversion to the social context (Komatsu et al., 2011) . These data fit with the μ receptor balance model (insufficient μ receptor tone) and further demonstrate that μ receptors are essential for establishing appropriate social behaviour. Interestingly, Oprm1 À/À mice were recently proposed as a monogenic mouse model of autism spectrum disorder (ASD) (Oddi et al., 2013; Becker et al., 2014) . ASD are complex neurodevelopmental diseases whose diagnosis is based on the detection of two types of behavioural symptoms (core symptoms): impaired social reciprocity and communication together with restricted, repetitive patterns of behaviour, interests or activities (Diagnostic and Statistical Manual of Mental Disorders: DSM-5). Co-morbid symptoms, variable in their occurrence and intensity, are frequently associated with ASD and encompass anxiety disorders, cognitive and motor deficits, aggressive behaviour, epileptic episodes, sleep disturbances, increased sensitivity to pain and altered gastrointestinal transit (Johnson and Myers, 2007; Robinson, 2012; Veenstra-VanderWeele and Blakely, 2012; White et al., 2012; Mazurek et al., 2013; Whyatt and Craig, 2013; Chen et al., 2016) . Intriguingly, in addition to deficits in social behaviour, Oprm1 À/À mice show stereotyped and perseverative behaviours, necessary to fulfil ASD criteria, as well as many of the co-morbid symptoms of ASD, namely, increased aggressiveness, exacerbated anxiety and motor clumsiness (Becker et al., 2014) , increased susceptibility to seizures (Jang et al., 2001; Grecksch et al., 2004; Becker et al., 2014) , impaired spatial learning (Jamot et al., 2003) , lowered nociceptive thresholds (Gaveriaux-Ruff and Kieffer, 2002) and reduced gastrointestinal motility (Roy et al., 1998) . The μ receptor null mice thus reproduce the broadest autistic syndrome ever reported in preclinical research, proving unique face validity. Moreover, Oprm1 À/À mice display anatomical, neurochemical and genetic landmarks of the disease, such as modified neuronal activation in anxietyand reward-associated brain structures, reduced striatal connectivity, altered synaptic morphology and monoamine levels in the striatum and modified expression of several candidate genes of autism, providing construct validity to the model (Becker et al., 2014; Mechling et al., 2016) . Finally, as regards predictive validity, risperidone and oxytocin, compounds that demonstrated efficiency in relieving autistic features in patients, also alleviated such symptoms in μ receptor null mice (Becker et al., 2014; Gigliucci et al., 2014) . Together, these results establish the Oprm1 À/À mouse line as a comprehensive model of ASD and demonstrate that genetic invalidation of μ receptors is sufficient to trigger an autistic syndrome in these rodents. Preclinical studies exploring MECP2-related genetic diseases further support the hypothesis of a tight link between ASD and μ receptors. The MECP2 gene codes for methyl-CpG binding protein 2, which binds DNA at methylated sites to either repress or activate transcription (Chahrour et al., 2008) . Genetic invalidation of Mecp2 in mice is a model for Rett syndrome, which includes autistic features; conversely, Mecp2 duplication mimics the MECP2 duplication syndrome, which also encompasses autistic symptoms (Lombardi et al., 2015) . Remarkably, μ receptor expression is decreased in the striatum of Mecp2 null mice (Kao et al., 2015) , consistent with a critical role of μ receptors in the striatum in supporting social behaviour. In mice bearing multiple copies of Mecp2, however, μ receptor expression is instead excessive, and breeding these animals with heterozygous Oprm1 +/À mice corrects both high μ receptor expression and deficient social interaction (Samaco et al., 2012) . These data fit the μ receptor balance model, with both deficient and excessive signalling having deleterious consequences (Figure 2 ). Most importantly, they further establish a connection between μ receptor and ASD, suggesting that defective μ receptor function could account for decreased social reward/motivation in these disorders.
Evidence for blunted reward processes in autism spectrum disorder
In search of the neurobiological underpinnings of disrupted social interactions in ASD, autism research had initially focused on cognitive impairments and involved theory-ofmind deficits or altered ability to infer other's mental states. Recently, however, motivational aspects of social skills have received more attention, and a social motivation theory has emerged (Dawson and Bernier, 2007; Chevallier et al., 2012) . In this framework, disrupted social interest in ASD patients would result from early deficits in social motivation, including interest in attending social stimuli, as well as enjoying and prolonging reciprocal social interactions. Such interactions being intrinsically rewarding (Fehr and Camerer, 2007; Neuhaus et al., 2010; Trezza et al., 2010) , the social motivation theory thus suggests that reward and/or social reward processes are altered in patients with ASD. Consistent with this hypothesis, numerous psychological studies have shown diminished sensitivity to the positive reward value of social stimuli in subjects with ASD (Scott- Van Zeeland et al., 2010; Chevallier et al., 2012; Lin et al., 2012; Sasson et al., 2012; Dubey et al., 2015; Kim et al., 2015) . Accordingly, electrophysiological (Stavropoulos and Carver, 2014; Gonzalez-Gadea et al., 2016) and pupillary (Sepeta et al., 2012) μ opioid receptor, social reward and autism 2014; Choi et al., 2015; Leung et al., 2015) are diminished in ASD patients presented with social stimuli (Figure 3 ). Of note, subjects with ASD also display hypo-activated NAc and caudate putamen (CPu) while anticipating negative social reinforcement and diminished activity in the social brain circuitry (including PFC and amygdala) in response to social touch (Kaiser et al., 2016) . As regards the amygdala and insular cortex, also involved in reward processing, studies have reported either hypo-activation (Kohls et al., 2012; Leung et al., 2015; Kaiser et al., 2016) or hyper-activation (Dichter et al., 2012b) in response to social stimuli in ASD subjects, possibly due to different experimental settings. Together, these data strongly support the hypothesis of deficient social reward in patients with ASD, as a likely consequence of abnormal activation of the brain reward circuit in social contexts.
Clinical data relative to other (non-social) rewarding stimuli appear less consistent. Concerning primary rewards, individuals with ASD were reported to display intact hedonic responses to sweet taste and stronger activation in brain reward regions (NAc, orbitofrontal cortex, amygdala and insula) in response to food cues (Cascio et al., 2012a) pointing to increased food reward in these patients.
In line with this, children with ASD were shown as less able to delay gratification when tested for a food reward (Faja and Dawson, 2015) . In contrast, ASD subjects exhibited diminished brain activation for pleasant (and neutral) tactile texture stimuli (Cascio et al., 2012b) and young children with ASD were impaired in learning an abstract rule from a discrete physical reward (small toy) (Jones et al., 2013) . Consistent with this, when presented with an object incentive, adults with ASD showed decreased activation in the dorsal ACC but increased activation in the paracingulate gyrus and other frontal regions (Dichter et al., 2012a) . These data suggest that reward processing for these stimuli is altered in ASD patients. Regarding secondary rewards, some studies have reported unchanged anticipation and processing of monetary reward (Dvash et al., 2014) and no modification of neural responses during monetary choices (Gonzalez-Gadea et al., 2016) in patients with ASD. In other reports, these patients were shown to be less sensitive to monetary incentive (Scott-Van Zeeland et al., 2010; Lin et al., 2012; Kohls et al., 2014) , notably when making effort-based decisions (Damiano et al., 2012) , and more sensitive to monetary loss (South et al., 2014) . Accordingly, imaging studies have disclosed hypo-activation in the mesocorticolimbic circuitry (NAc,
Figure 3
Brain areas differentially activated in patients with ASD versus controls during social (left panel) or monetary (right panel) reward anticipation and/ or processing. Lateralization of brain responses (right or left hemisphere) was not taken into account to simplify the proposal. Comparing brain activation patterns for social and monetary reward reveals a common hypoactivation of a frontostriatal circuit including key regions for reward processing that are ACC, NAc and CPu in patients with ASD. The nature of stimuli used for experiments (images of faces, verbal praise and social reinforcement), tasks performed (stimulus presentation vs game or learning task for example) and timing (anticipation vs reward processing) varied across studies, possibly accounting for discrepancies in the level of activation of some structures (IC, AMG and OFC). Brain regions belonging to the reward circuitry are highlighted in orange. ACC, anterior cingulate cortex; AMG, amygdala; dACC, dorsal anterior cingulate cortex; dlPFC, dorsolateral prefrontal cortex; HPC/EC, hippocampus/enthorinal cortex; IC, insular cortex; MB, midbrain; MFG, medial frontal gyrus; OFC, orbitofrontal cortex; paraCC, paracingulate cortex; PC, parietal cortex; pCC, posterior cingulate cortex; PCG, precentral gyrus; PG, parahippocampal gyrus; SFG, superior frontal gyrus; STG, superior temporal gyrus; vPFC, ventral prefrontal cortex. Reichelt et al., 2012 CPu and midbrain) during monetary anticipation or outcome in ASD patients (Kohls et al., 2012; Dichter et al., 2012a; Dichter et al., 2012b; Richey et al., 2014) (Figure 3) . Moreover, children with ASD were found to display reduced activation of the right CPu when anticipating monetary loss . Finally, when reward stimulus was a positive feedback ('Correct!' printed on screen) versus negative feedback ('incorrect!'), young adults with ASD displayed impaired ability to develop an effective reward-based working memory (Solomon et al., 2015) . These data converge towards altered processing of secondary reward in ASD patients. However, ASD subjects can attribute higher positive ratings to non-social stimuli whenever these stimuli match their restricted interests (trains and electronics) (Sasson et al., 2012; Watson et al., 2015) . Non-social reward processes thus appear unevenly affected by ASD, with food reward and restricted interests showing increased motivational value, whereas other stimuli show blunted motivational properties. Methodological issues should be mentioned, though, that may limit previous conclusions. Indeed, a major difficulty in clinical ASD research lies in recruiting patients. Notably, sample size in a majority of studies is small and the age of participants is highly heterogeneous (young children, adolescents and adults) as well as patient's use of psychotropic medications or involvement in behavioural therapy programs, which has significant consequences on reward processing (Pankert et al., 2014) . Most importantly, clinical studies suffer from a major IQ bias: They focus on a population of subjects with IQ in a normal range, namely, higher functioning ASD patients. This bias is essentially due to technical issues, as most psychological tasks and imaging settings in previous studies are too demanding and restrictive for lower functioning subjects. The possibility that the latter patients present more severe reward deficits has thus never been explored. Of importance though, conditioned learning mechanisms are set very early in the course of human infant development (Rovee-Collier, 1999 ) and depend tightly, as regards appetitive aspects, on the integrity of the reward system (Dayan and Balleine, 2002; O'Doherty et al., 2016) . Major deficits in reward processing may thus result in cognitive impairment, such as observed in low functioning ASD patients, highlighting the interest of evaluating reward in this population.
In conclusion, clinical data have demonstrated deficient reward processing in patients with ASD, for social and secondary (monetary) stimuli. The neurobiological substrates
Figure 4
Copy number variation in the OPRM1 gene of patients with ASD. OPRM1 is located on chromosome 6 at the q25.2 position. The map was build based on the integrated catalogue of copy number variants (CNVs) associated with ASD from the Simons Foundation Autism Research Initiative resource website (https://gene.sfari.org/autdb/CNVHome.do; September 2016). We identified 10 patients from this database displaying CNVs that affect the OPRM1 gene (eight deletions and two duplications) (Kaminsky et al., 2011; Sanders et al., 2011; Halgren et al., 2012; Battaglia et al., 2013) . No CNVs were detected in controls, some of which showed mutations immediately beyond OPRM1 boundaries. Remarkably, OPRM1 CNVs were all detected in low-functioning ASD subjects (with intellectual disability). ID, intellectual deficiency; IQ, intellectual quotient.
of this deficit remain to be identified, and one possible candidate is a dysfunction of the opioid system.
The opioid hypothesis in autism
As a straightforward consequence of BOTSA (Panksepp et al., 1978) , Panksepp proposed for the first time in 1979 that autism would be an emotional disorder caused by excessive brain opioid activity and, therefore, that opioid antagonists should be beneficial to treat this pathology (Panksepp, 1979) . The last hypothesis was later tested by administering naltrexone to ASD patients. Several clinical trials showed beneficial effects of naltrexone in reducing hyperactivity and irritability, but failed to detect an improvement in core autistic symptoms (reviewed in (Roy et al., 2015) ), except maybe in a subgroup of patients with high blood levels of β-endorphins (Leboyer et al., 1992; Bouvard et al., 1995) . Consistent with the excessive opioid hypothesis, several studies have reported increased (but also decreased) levels of opioid peptides in plasma, urinary and cerebrospinal fluid samples from patients with ASD (Table 2 ). Reichelt and colleagues proposed a dietary origin for urine peptides (Reichelt et al., 1991) and therefore recommended a glutenand casein-free diet to relieve ASD (Knivsberg et al., 1999) . Technical issues were raised, however, regarding the concentrations of urinary opioid peptides that challenged Reichelt's hypothesis and led to a still active scientific controversy. In further questioning of the excessive opioid theory, reviews and meta-analyses have examined clinical evidence for the efficacy of dietary intervention in autism and found a lack of consistent effects (Dosman et al., 2013; Mari-Bauset et al., 2014; Lange et al., 2015) . In sum, technical concerns and disappointing clinical results have argued against the excessive opioid theory of autism and, more generally, dissuaded the scientific community from considering dysfunction in the opioid system as a plausible neurobiological substrate for autism.
The hypothesis of excessive opioid activity in autism fits into the excessive opioid tone window of our μ receptor balance model (Figure 2) . However, this model also predicts that ASD could result from insufficient opioid tone. Interestingly, there is clinical evidence supporting both propositions. Dosage studies have examined levels of opioid peptides in various biological samples from patients with autism. As regards plasma samples, most studies have detected an increase in circulating β-endorphin in subjects with ASD (or their mothers) or Rett syndrome (Table 2 ). Whether such increase would reflect an excessive opioid tone in these patients or, instead, reflects a compensation for defective opioid signalling, as suggested by abnormal β-endorphin immunoreactivity (Leboyer et al., 1994) or decreased μ receptor expression in a mouse model of Rett syndrome (Kao et al., 2015) , has not been explored yet. Of note however, low doses of naltrexone, known to stimulate μ receptor expression (Brown and Panksepp, 2009) , significantly relieved autistic symptoms in several ASD patients (Leboyer et al., 1992; Bouvard et al., 1995) . Regarding cerebrospinal fluid and urine samples, levels of β-endorphin or, more generally, opioid peptides appear inconsistent, possibly due to methodological issues. Urinary exogenous (presumably dietary) opioid peptides have been detected in several studies (Table 2) . Together, these data argue for a link between opioid tone and ASD, in either direction (excessive or deficient tone). Genetic studies further support the existence of such connection. We browsed the SFARIgene 2.0 database (https://gene.sfari.org/autdb/Welcome.do) in search for mutations affecting opioid genes in ASD patients. We failed to find mutations in genes coding for the precursors of endorphins (POMC) or dynorphins (PDYN) and for δ or κ receptors (OPRD1, OPRK1). We found one patient with a genetic deletion including PENK, coding for proenkephalin (Kaminsky et al., 2011) . Strikingly, however, we found 10 patients with mutations affecting the OPRM1 gene (Figure 4 ). For comparison, mutations in CNR1, coding for the CB 1 cannabinoid receptor, another candidate gene for ASD involved in reward processing (Chakrabarti et al., 2006) , are not reported in the SFARIgene 2.0 database. In addition, OPRM1 mutations are all associated with intellectual deficiency, suggesting that compromised μ receptor function in humans can lead to IQ impairment. Genetic data thus demonstrate that genetic μ receptor ablation is sufficient to produce ASD in humans, as it is in mice (Becker et al., 2014) . Direct genetic mutation, though, is not the only way to impair the expression and function of a GPCR, as illustrated by the effects of Mecp2 genetic manipulation on μ receptor expression in mice. Whether mutations in other candidate genes for autism identified from sequencing studies could affect μ receptor signalling thus needs to be carefully explored.
Conclusions
Recent advances in brain imaging and sustained efforts towards identifying the genetic and neurobiological substrates of social impairment in ASD, including characterization of mouse models, have revived the exciting field of opioids and social behaviour. These studies have provided the demonstration that, among factors of the opioid system, μ receptors are the key substrate for the control of social behaviour. In an attempt to better describe the role of μ receptors in such control, we propose here a new model, the μ receptor balance model, in which both deficient and excessive μ receptor signalling results in social behaviour impairments. How this model could apply to other opioid-dependent functions would need further investigation. Importantly, altered μ receptor function is clearly sufficient to hamper social abilities, making it a plausible contributor to ASD. Dedicated studies are now required to explore the necessity of μ receptor dysfunction for social impairment in such pathologies. Remarkably, pharmacological treatments can relieve autistic-like symptoms in μ receptor null mice (Becker et al., 2014; Gigliucci et al., 2014) , suggesting that whether or not μ receptor dysfunction is a core mechanism in ASD, promising therapeutic strategies exist that can overcome such dysfunction. the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015) .
